Background: Anaphylaxis during anaesthesia is a serious complication for patients and anaesthetists. There is little published information on management and outcomes of perioperative anaphylaxis in the UK. Methods: The 6th National Audit Project of the Royal College of Anaesthetists (NAP6) collected and reviewed 266 reports of Grade 3e5 anaphylaxis from all UK NHS hospitals over 1 yr. Quality of management was assessed against published guidelines. Results: Appropriately senior anaesthetists resuscitated all patients. Immediate management was 'good' in 46% and 'poor' in 15%. Recognition and treatment of anaphylaxis were prompt in 97% and 83% of cases, respectively. Epinephrine was administered i.v. in 76%, i.m. in 14%, both in 6%, and not at all in 11% of cases. A catecholamine infusion was administered in half of cases. Cardiac arrests (40 cases; 15%) were promptly treated but cardiac compressions were omitted in half of patients with unrecordable BP. The surgical procedure was abandoned in most cases, including 10% where surgery was urgent. Of 54% admitted to critical care, 70% were level 3, with most requiring catecholamine infusions. Ten (3.8%) patents (mostly elderly with cardiovascular disease) died from anaphylaxis. Corticosteroids and antihistamines were generally administered early. We found no clear evidence of harm or benefit from chlorphenamine. Two patients received vasopressin and one glucagon. Fluid administration was inadequate in 19% of cases. Treatment included sugammadex in 19 cases, including one when rocuronium had not been administered. Adverse sequelae (psychological, cognitive, or physical) were reported in one-third of cases. Conclusions: Management of perioperative anaphylaxis could be improved, especially with respect to administration of epinephrine, cardiac compressions, and i.v. fluid. Sequelae were common.
The 6th National Audit Project of the Royal College of Anaesthetists (NAP6) was performed to characterise the incidence, risk factors, current management, clinical outcomes, and investigation of perioperative anaphylaxis in the UK. This paper describes the management and outcome data, and, based on this, makes recommendations for future practice. Successful management of perioperative anaphylaxis is critically dependent on early recognition and prompt initiation of specific treatment. Recognition that a critical event occurring during anaesthesia is likely to be anaphylaxis might not be straightforward and the differential diagnosis is wide. Rash, the classical sign of an allergic reaction, is present in approximately half of cases, but might be not visible under surgical drapes or be delayed, especially in more severe cases. Hypotension requiring vasopressor drugs, which is usually the first sign of perioperative anaphylaxis, 1 is also common during uncomplicated general 2 or neuraxial anaesthesia. It is only when the BP does not respond to treatment that less common causes of hypotension are sought, including: myocardial ischaemia; cardiac arrhythmia; thrombotic, amniotic fluid, fat, bone cement, air, or carbon dioxide embolism; pneumothorax; covert haemorrhage; and anaphylaxis. Similarly, bronchospasm is the first clinical feature in 18% of cases of perioperative anaphylaxis, 1 but is not uncommon during general anaesthesia, especially in asthmatic patients, and anaphylaxis might not be the first differential diagnosis. It is generally agreed that epinephrine (adrenaline) is the mainstay of management and is recommended in all published guidelines. 3e11 Having both a-and b-agonist properties, epinephrine has compelling theoretical advantages in the treatment of anaphylaxis by ameliorating many of the pathophysiological processes (Fig. 1) .
Although metaraminol is a second-line treatment in Association of Anaesthetists of Great Britain and Ireland (AAGBI) guidelines, 3 it is widely available in UK anaesthesia settings for management of hypotension. Several case reports describe survival after use of i.v. vasopressin (antidiuretic hormone) 2e15 units in the management of intractable perioperative anaphylaxis, 12e15 and this drug is included in the Australasian guidelines. 10 The benefit of epinephrine is likely to be reduced in the presence of b-blockade. There are single case reports of glucagon use in b-blocked patients leading to rapid resolution of hypotension. 16, 17 European 11 and Australasian 10 guidelines recommend epinephrine every 5 min until response, but it is not known how commonly glucagon and vasopressin are used to treat perioperative anaphylaxis in UK practice. There are no published randomised controlled trials investigating the efficacy of corticosteroids in the acute management of anaphylaxis and few published observational data on the pattern of their use in practice. The rationale for corticosteroid administration in anaphylaxis is an extrapolation of their effectiveness in the long-term management of allergic asthma, 18 and hydrocortisone is recommended in published guidelines. The use of antihistamines in relatively minor out-ofhospital allergic reactions benefits urticaria and pruritus. A Cochrane review of H1 antihistamines for anaphylaxis was unable to make any recommendations because of lack of evidence. 19 This statement, together with side-effects of promethazine, has resulted in some expert groups recommending that antihistamines should not be administered. 10 We aimed to establish whether administration of chlorphenamine, the most commonly used antihistamine in the UK, influenced outcome. We also sought to determine to what extent sugammadex has been incorporated in current management of perioperative anaphylaxis. Anaphylaxis is associated with an acute decrease in venous return and cardiac output (Fig. 1) , and there is consensus for rapid i.v. infusion of crystalloid fluids. Recent guidelines emphasise the need to give rapid, repeated i.v. fluid challenges whilst monitoring the response: Australasian guidelines recommend giving repeated boluses of 20 ml kg À1 . 10 There are few data concerning i.v. fluid management in management of perioperative anaphylaxis, and we sought to obtain this information.
Little is known about the outcomes of perioperative anaphylaxis. We sought to establish the influence of patient characteristics, concomitant medication, comorbidities, and the quality of resuscitation. Lastly, we aimed to characterise perioperative anaphylaxis in two important groups: obstetric patients and children.
Methods
Methods are described briefly here but are discussed in detail in an accompanying paper. 20 All UK NHS hospitals took part and each had a Local Coordinator, a consultant anaesthetist, responsible for delivering the project. There were four elements to the project (reported in previous 21, 22 or accompanying papers 1, 20, 23, 24 ); relevant here was a 1 yr prospective collection of anonymised case reports of lifethreatening perioperative anaphylaxis, undertaken in 2015e16. Submission of cases entailed completion of a detailed form that included patient characteristics, description of the event, its management, patient outcomes, and allergy clinic investigations. Analysis of allergy clinic investigation is reported in another paper and therefore not discussed in detail here. 25 Eligible cases were reviewed by a multidisciplinary panel, details of which are described in the methods paper. 20 The quality of immediate management was assessed and classified including factors such as timeliness, accuracy, and completeness. Promptness of treatment was assessed on a case-by-case basis (generally <5 or <10 min) based on difficulty in making the diagnosis. In doing this we also referred to current guidelines of the AAGBI and Resuscitation Council of the United Kingdom (RCUK) on management of perioperative anaphylaxis 9 and cardiac arrest 26 where relevant.
Regarding resuscitation, after taking external expert advice, the panel used a systolic BP threshold of <50 mm Hg as the point at which chest compressions were indicated in adult patients. The rationale for this is discussed in detail in the accompanying paper 20 but is based on the findings that invasively measured systolic BP <50 mm Hg is associated with pulselessness with a 90% positive predictive value 27 and that non-invasive methods will underestimate hypotension when it is severe. 28 When the lowest recorded BP was <50 mm Hg and cardiopulmonary resuscitation (CPR) was not started, this was deemed to be suboptimal care. The overall initial management was graded as 'good', 'good and poor', or 'poor', 20 taking into account airway management, prompt and comprehensive anaphylaxis-specific pharmacological treatment, administration of i.v. fluids and initiation of cardiac compressions, if required. Although administration of epinephrine is the accepted standard for the immediate management of perioperative anaphylaxis, the review panel recognised that anaphylaxis is an uncommon cause of hypotension or bronchospasm during anaesthesia. It is therefore reasonable for anaesthetists to start treatment with vasopressors and bronchodilators such as metaraminol, ephedrine, and salbutamol before instituting anaphylaxis-specific treatment, unless anaphylaxis was clinically-obvious from the outset.
Results here are based on a dataset of the 266 reviewed cases of confirmed anaphylaxis. For some analyses, a smaller dataset is used. The quality of delivered care is based on an indepth panel review of 184 cases. 
Statistical analysis
Data are presented as median and range.
To examine the impact of chlorphenamine on outcome, we performed a logistic regression model. Variables included initial resuscitation drugs (epinephrine bolus, corticosteroids, metaraminol, ephedrine, and chlorphenamine); patient factors (age group intervals excluding children and age >75 yr because of small numbers) and ASA physical status (excluding ASA 5 because of few cases). Outcome was level of harm (no harm, low, moderate/severe harm/death). 20 A Fisher exact test was used to examine association between chlorphenamine administration and good quality care as judged by the review panel. A Fisher exact test was used to compare incidences of anaphylaxis between adults and children and between nonobstetric and obstetric adult patients.
Results

Quality of resuscitation
Resuscitation was performed by an anaesthetist of appropriate grade in all cases. The review panel considered that overall management was good in 46% cases; good and poor in 39%, and poor in 15% (Fig. 2) . Recognition of a critical incident and suspicion of anaphylaxis was within 5 min in 60% and 49% of cases, respectively. By 10 min, the corresponding figures were 78% and 74%, respectively. Recognition of anaphylaxis and treatment were judged prompt in 97% and 83% of cases, respectively (Fig. 3) .
Specific treatment for anaphylaxis after the first clinical feature was started in <5 min in 64% of cases and <10 min in 83% (Fig. 4) . Reported reasons for delay in starting anaphylaxis-specific treatment included confounding differential diagnoses such as pulmonary thromboembolism, tension pneumothorax, gas embolism during laparoscopy, primary cardiac events, surgical haemorrhage, and hypotension associated with neuraxial block.
Airway management
Airway management was judged appropriate in 98.8% of cases; in 1.2% of cases, it was judged that tracheal intubation should have been performed. Airway swelling, airway difficulty, and complications were uncommon. Tracheal intubation was performed as part of resuscitation in 13% of patients; in the majority this involved removal of a supraglottic airway and replacement by a tracheal tube. In three (1.1%) cases, the tracheal tube was removed and replaced as a result of suspected oesophageal intubation as part of the differential diagnosis. A front of neck airway was instituted in one patient who developed laryngeal oedema and stridor, but other details of this case were scarce. In seven patients, it was necessary to re-intubate the trachea after completion of the primary surgical procedure; in no case was re-intubation difficult because of laryngeal swelling.
Vasoactive drugs
Pharmacological treatment was judged prompt in 84% and comprehensive in 99% of cases. The vasoactive drugs administered are shown in Figure 5 . Epinephrine was administered in 82% of cases, as i.v. boluses in 76%, with administration and doses administered increasing as reaction severity increased. The median i.v. total dose was 0.2 mg, Metaraminol boluses were administered in 69% of patients, of whom 74% also received epinephrine. Phenylephrine (mostly in obstetric cases) was administered by i.v. bolus in 7.8% of cases and by infusion in 3.5%. An i.v. infusion of norepinephrine (noradrenaline) was administered in 19% of cases. Only two patients received vasopressin (antidiuretic hormone) and one received glucagon. In both cases these drugs were given late in the resuscitation process and each was preceded by ephedrine, metaraminol, and epinephrine.
Bradycardia, which was present in 13% of all cases, was treated with glycopyrronium in 4.3% and atropine in 6.2%, a third in association with cardiac arrest. Tachyarrhythmia was rare, being treated once with amiodarone, which was also used during the management of four cases of cardiac arrest. No other antiarrhythmic drugs were used to treat tachyarrhythmia.
Intravenous fluids
Fluid management was judged inappropriate, almost always as insufficient, in 19% of cases. Most (98%) of patients received i.v. crystalloids in the first hour after the reaction, 86% during the subsequent 2 h and 69% 3e5 h after the event. The median volume administered during each of these time periods was 1 L (range 0.1e6.0 L), 1 L (range 0.1e3.0 L), and 0.5 L (range 0.1e4.5 L). The only i.v. colloids administered during the first hour after the anaphylactic event were succinylated gelatin products in 25 (9%) cases.
Corticosteroids
I.V. hydrocortisone was administered in 83% of cases (one to four doses, median dose 200 mg) and dexamethasone (administered after the event) in 16% of cases (median dose 6 mg). In 8.7% of cases, both drugs were administered during the event. Two patients received methylprednisolone. Of note, dexamethasone was also given before the event in 19% of cases. Thirty-four patients (12.8%) did not receive a steroid, including four fatalities.
Antihistamine drugs
Intravenous chlorphenamine was administered in 74% (median 10 mg, 5e40 mg; Table 1 ) and i.v ranitidine in 5.3% of cases. Nine (3%) patients received both drugs. Chlorphenamine administration was associated with an increased probability of 'no harm' and a decreased probability of a 'moderate/severe harm and death': odds ratios 2.20 (1.05e4.58) and 0.41 (0.18e0.91), respectively. Chlorphenamine had no effect on the probability of 'low harm'. However, in order to exclude chlorphenamine as a surrogate for good (as opposed to 'poor' or 'good and poor') clinical management (noting that chlorphenamine administration was not used as a measure of quality of care during panel discussions), we performed a Fisher exact test. This confirmed a significant association between administration of chlorphenamine and care being judged as good (P<0.005). Thus, we were not able to determine with any clarity whether administration of antihistamine was associated with harm or benefit.
Sugammadex
Sugammadex was administered within 6 h of the event in 19 (7.1%) cases (median dose 300 mg, range 150e1200 mg). Patients had received rocuronium in all but one case, in which atracurium had been administered. The suspected trigger agent was rocuronium in nine cases, and the actual culprit in seven. The other culprits were teicoplanin, co-amoxiclav, and atracurium. In the seven cases of rocuronium-induced anaphylaxis, after administration of sugammadex, no 
Fatal cases
Immediate management was prompt in all but one of the 10 fatal cases and all resuscitations followed a guideline and were managed by a consultant. Nine had a cardiac arrest during the event and one did not. Resuscitation from cardiac arrest, in the nine relevant cases, was prompt, prolonged, and extensive. CPR took place for a median 39 min, and in all cases for >25 min. Resuscitation included extracorporeal membrane oxygenation in one patient and immediate cardiac catheterisation to explore or manage an acute coronary syndrome in two patients. Epinephrine i.v. was administered in all cases including an infusion in five. A median of five doses (5 mg) epinephrine was administered (range 2e13 mg). No patient received i.m. or intraosseous epinephrine. Ephedrine, metaraminol, glycopyrronium, and atropine were used early in resuscitation and five patients received norepinephrine, two vasopressin, and one glucagon (administered 65 min after the reaction). Half of cases received chlorphenamine and hydrocortisone. Sugammadex was not used. Fluid resuscitation volumes were relatively modest 1e4.5 L (median 1.5 L) in the first hour and 1e9.5 L, (median 1.5L) in the first 5 h: only one patient received >4 L in total. Five patients did not survive initial resuscitation, while five did, one of whom died soon after. Of the four remaining patients, all were admitted to ICU and all survived at least 1 week, but all deaths occurred in <30 days. Four patients developed multiple organ failure. A mast cell tryptase sample was sent in all cases and a dynamic change was identifiable in five cases. Mast cell tryptase results are discussed elsewhere. 25 There were no episodes of recrudescence of anaphylaxis. Good elements of care were: appropriately senior resuscitators (10/10); prompt recognition of the critical event (9/ 10); prompt recognition of anaphylaxis (9/10); appropriate airway management (10/10) and prompt initiation of cardiac compressions (9/10, one uncertain). Inadequate fluid administration was a recurrent theme.
Cardiac arrest
Cardiac arrest was reported in 40 (15%) patients: five did not survive the cardiac arrest, four died after admission to critical care and 31 survived. In 11 patients, cardiac arrest occurred within 5 min of trigger administration, although others were preceded by prolonged hypotension. All these patients received cardiac compressions for a mean duration of 14 min (range 1e60 min). It was generally prolonged in those who died (see above) but brief in those who survived: median 8 min (interquartile range 2e8 min) in survivors. The event was generally promptly recognised and treated. Delay in managing anaphylaxis was a result of slow diagnosis or uncertain diagnosis (one case each) and loss of i.v. access (one case). Quality of resuscitation is summarised in Table 2 . On average, five doses of epinephrine i.v. were administered (total mean 5 mg, range 0e12 mg), notably similar in those patients who died or survived. Half of survivors received an epinephrine infusion after initial resuscitation. Second-line drugs included norepinephrine to 15 patients, vasopressin to two (one of whom died and one survived), glucagon to one (who died), lipid emulsion to two and sugammadex to one. Chlorphenamine and steroid were given to approximately 75% of patients during resuscitation. Fluid volumes were modest; median volume 1.8 L (range 0e4.5 L) during Table 2 Quality of resuscitation and outcomes in patients who died compared with those who survived cardiac arrest, and those who experienced profound hypotension or did not *One patient who subsequently died did not have a cardiac arrest at the time of the event Table 2 .
Profound hypotension
In >40% of cases the lowest systolic arterial pressure was <50 mm Hg or unrecordable. Chest compressions were initiated in 28 (50%) of those with an unrecordable BP and in five (9%) with systolic arterial pressure <50 mm Hg. Prompt initiation of chest compressions for arterial pressure <50 mm Hg or unrecordable was reported in 23% of cases. In the group with profound hypotension without cardiac arrest, failure of prompt and complete pharmacological treatment and fluid administration was noted somewhat more frequently than in other groups and care was more frequently judged to be poor. Patient characteristics, outcomes, and quality of care are summarised in Table 2 .
Discontinuation of the trigger agent
The suspected trigger agent was discontinued in 22 of the 26 cases where this would have been possible. Agents that were not discontinued were i.v. gelatin, a chlorhexidine-coated central venous line, a second dose of co-amoxiclav, and a second dose of protamine. The actual trigger agent was not discontinued in four of the fourteen cases where this would have been possible: i.v. gelatin, administration of a second dose of protamine, and two instances of retained chlorhexidine-coated central venous line.
Continuation of surgery
In one-third of cases the procedure was unchanged but, in more than half of cases the intended surgery was not started. In a small proportion of cases the procedure was modified or abandoned. Median severity was Grade 4 in the abandoned cases and Grade 3 in continued cases. In two cases, cardiopulmonary bypass was used as part of the resuscitation process.
Unplanned hospital stay and critical care admission
The median unplanned hospital length of stay as a result of anaphylaxis was 1 day, but there was a wide range: 18% >2 days; 12% >3 days; 8.3% >4 days; and 6.6% > 5 days. The longest unplanned length of stay was 150 days. Of 144 (54%) patients transferred to critical care, the majority (70%) were for level 3 care. The median duration of level 3 care was 1 day (range 1e9 days), and of level 2 care was 1 day (range 1e25 days). Six patients required level 3 care and five level 2 care for >2 days. No patient required an increase in their level of care after admission to critical care. Data on the use of vasopressors and bronchodilators were available for 135 and 119 patients, respectively. While in critical care, 84/135 (63%) of patients received vasopressors or inotropes and 6/119 (5.0%) bronchodilators. Of 84 patients requiring vasopressor or inotrope infusions in critical care, 29 (34%) received epinephrine, 19 (23%) both epinephrine and norepinephrine, 13 (15%) norepinephrine, and the remainder other inotropic drugs.
Outcomes (cases of all severity)
The severity of physical harm (see accompanying paper for definitions) 20 identified by the review panel was none in 8%;
low in 51%; moderate in 34%; severe in 0%; death in 4%; and uncertain in 3%. Concomitant b-adrenergic blocking drugs were associated with greater severity: 60% of fatalities were taking a b-blocker compared with 18% of all cases although causality cannot be proved. We asked about physical and psychological sequelae after the event. Data were recorded poorly, so any estimates must be judged as minima. More complications were recorded in the section of the case report form completed before allergy clinical referral (104 sequelae: 67 mild, 29 moderate and eight severe) than in that completed after the allergy clinic visit (73 sequelae: 41 mild, 27 moderate, and five severe). Anxiety about future anaesthetics was the most commonly reported consequence, accounting for more than half of longer-term consequences, in three cases this extended to symptoms of posttraumatic stress disorder. Ten patients reported problems with mood, memory, or coordination. There were 13 reports of myocardial infarction, acute kidney injury, or new shortness of breath.
As a result of anaphylaxis, cancer surgery was delayed in 19 (7.1%) cases, urgent non-cancer surgery in eight (3%), nonurgent surgery in 76 (29%), and other treatment was delayed in nine (3.4%) cases. Total hospital stay was extended as a result of anaphylaxis in 75% of patients (median 1 day, range 0e150 days).
Obstetric cases
We identified eight obstetric cases in NAP6, all of which were Grade 3. The NAP6 Activity Survey 23 estimated that 233 886 obstetric anaesthetics are administered per annum in the UK, giving an incidence of severe obstetric perioperative anaphylaxis of 3.4 per 100 000 (95% CI: 1.5e6.7 per 100 000). The incidence in obstetric patients is therefore lower than in nonobstetric adult patients (247 cases in 2 489 428 patients: 9.9 per 100 000, 95% CI: 8.7e11.2 per 100 000, Fisher exact P 0.001). Six patients received neuraxial anaesthesia and two general anaesthesia. Six cases occurred in association with anaesthesia for Caesarean section, most commonly after delivery of the baby. There were no cardiac arrests, maternal, or neonatal deaths. All patients developed hypotension, in some cases profound. In four of six patients who developed severe anaphylaxis during neuraxial anaesthesia, a common feature was the patient complaining of feeling unwell before the onset of hypotension or other clinical signs. Hypotension commonly developed at a time when spinal-induced hypotension would have been anticipated to have settled.
A consultant anaesthetist was involved in the management of all the cases. In five cases there was prompt treatment, but in three cases there was a delay in diagnosis and treatment was delayed. Resuscitation drugs differed from those used in non-obstetric cases: six patients received phenylephrine, four epinephrine, and three both drugs. Fluid management was appropriate in all cases. An anaphylaxis pack was used to assist management in only two cases. In four cases, overall care was judged as good and in one case was judged as good and poor.
Mast cell tryptase tests were sent in all cases. In six cases, these were raised or there was a dynamic change. The reaction was allergic anaphylaxis in five cases, anaphylaxis notspecified in one cases and uncertain in two. Identified culprits were chlorhexidine, atracurium, succinylcholine (suxamethonium), and ondansetron and in four cases no trigger was identified.
Maternal and neonatal outcomes were good in all cases. None of the women who experienced anaphylaxis during neuraxial anaesthesia required tracheal intubation. For three women hospital discharge was delayed and one patient reported anxiety about future anaesthesia.
Paediatric cases
Eleven cases of perioperative anaphylaxis in patients aged <16 yr were reported, three of which were emergency procedures. With an estimated 403 000 paediatric cases performed per annum, the incidence of Grade 3e4 anaphylaxis is 2.7 per 100 000 paediatric anaesthetics (95% CI: 1.4e4.9 per 100 000). The incidence in paediatric patients is therefore lower than in adult patients (255 cases in 2 723 314 patients: 9.4 per 100 000, 95% CI: 8.4e10.6 per 100 000, Fisher exact P<0.001).
Two patients had well-controlled asthma. Six cases presented in the operating theatre, three in the anaesthetic room, one during transfer from the recovery room to the ward and one in the radiology department. Seven cases presented after induction and before surgery. The first clinical feature was bronchospasm, or high airway pressures in seven (64%) cases with hypotension being the presenting feature in two, tachycardia in one, and non-urticarial rash in the remaining case.
Bronchospasm presented within 5 min, whereas hypotension was generally slower in onset. A decrease in end-tidal carbon dioxide concentration was noted in three cases with an absent capnography trace in two of these at some point. Two cases exhibited non-laryngeal oedema, which was delayed in one case. There were no fatalities in children. The clinical features present at any time during the reaction are shown in Figure 6 . All cases were judged Grade 3 by the index anaesthetist: on panel review, six were judged as Grade 4.
The review panel judged that clinical management was good in four cases, good and poor in two cases, and was poor in a single case (where epinephrine was not administered). A consultant was present during resuscitation in all cases. AAGBI guidelines were used in five and RCUK guidelines in one. In seven cases, there was immediate access to a guideline as a laminated document.
Specific treatment for anaphylaxis was started within 5 min in six of the seven cases where bronchospasm or high airway pressures were the presenting feature. When hypotension or tachycardia were the presenting features, specific treatment tended to be started later. Epinephrine was administered in 10 cases, either i.v. or i.m., and an infusion was required in four cases. Other vasopressors were used in small numbers of cases. Eight patients received chlorphenamine and eight hydrocortisone. Two patients did not receive a corticosteroid. One patient received atropine. No patients received phenylephrine, vasopressin, glucagon, glycopyrronium, sugammadex, or magnesium sulfate. Ten patients received i.v. crystalloid, one i.v. gelatin, and one no i.v. fluid. The volume of crystalloid administered during the first hour was 12e75 ml kg À1 (median 20 ml kg À1 ), between 1 and 3 h 3e25 ml kg À1 (median 9 ml kg À1 ), and during the subsequent 2 h 6e20 ml kg
À1
(median 8 ml kg À1 ).
In six cases the procedure was abandoned and four of these were rescheduled, in all cases except one judged to be appropriate. Three patients were transferred to HDU/ICU as a result of the event, including one to a different hospital.
Eight cases had at least one mast cell tryptase sample obtained, with four showing elevation or dynamic changes. The reaction was allergic anaphylaxis in three cases, non-allergic anaphylaxis in one case, anaphylaxis not-specified in two cases and uncertain in five. Culprit agents were: atracurium in three cases and one each of succinylcholine, aprotinin, cefuroxime, ibuprofen, and cryoprecipitate. The trigger was not confidently identified in the three remaining cases. The mechanism of the reaction to ibuprofen was judged to be nonallergic anaphylaxis. Overall allergy clinic investigation for eight fully reviewed cases was good in one, good and poor in three, and poor in four.
Following resuscitation and clinical recovery, one child was reported as being withdrawn and angry and one child reported anxiety about potential further anaesthesia. Seven cases were reported through the Trust's local critical incident reporting system but only one case was recorded as being reported to the Medicines and Healthcare products Regulatory Agency, and two patients were issued with a hazard alert by the anaesthetist.
Concordance
Concordance between triggers suspected by the anaesthetist and identified by the panel is discussed in greater detail in a paper exploring allergy clinic investigation of the NAP6 cohort. 25 Amongst cases with an identified trigger, overall concordance was 75% between the anaesthetist and the panel. However, anaesthetists were likely to over-identify neuromuscular blocking agents as triggers and to fail to recognise chlorhexidine-induced anaphylaxis.
Communication
The panel judged that there were considerable shortcomings in communication between the anaesthetist and the patient after the event. Information given to the patient by the anaesthetist about which drugs or other substances they should avoid before attending an allergy clinic for investigation was oral in 27%, written in 20%, both in 39%, and none in 14%. In 222 cases where this information was available, 29% were issued with a hazard warning card, 39% of these by the index anaesthetist. 
Discussion
Key findings
The key findings of the NAP6 survey of anaphylaxis are summarised as follows: 
Immediate management: all cases
We are unaware of any previous study investigating the management of perioperative anaphylaxis in such detail. It is reassuring that resuscitation involved a consultant or other career grade anaesthetist in all cases. The majority (89%) of UK patients are anaesthetised by consultant or career grade anaesthetists 23 ; nevertheless, trainees were willing to call for help and the theatre team contributed effectively to management in almost 90% of cases. Recognition of perioperative anaphylaxis may be difficult but nevertheless was prompt in 83% of cases.
Overall quality of management was judged 'good' in slightly less than half of the cases. The deficits were multifactorial and included insufficient i.v. fluids (19% of cases), non-administration or late administration of epinephrine (18%), delays in recognising anaphylaxis and starting specific treatment, and lack of cardiac compressions where there was profound hypotension.
Epinephrine and fluids
The beneficial actions of epinephrine include venoconstriction which increases venous return, reduced capillary permeability, increased cardiac contractility and cardiac output, bronchodilatation, and inhibition of mast cell and basophil mediator release. Early administration of epinephrine is associated with improved outcomes in out-of-hospital anaphylaxis. 29 McLean-Tooke and colleagues 30 concluded that epinephrine is not contraindicated in patients with coronary artery disease as continuing anaphylaxis is likely to reduce coronary artery perfusion further. However, excessive dose or over-rapid i.v. administration can cause arrhythmias. We found no evidence that epinephrine caused arrhythmia and the dose in survivors and non-survivors of cardiac arrest did not differ. I.V. epinephrine is more likely than i.m. to result in cardiac complications in treatment of out-of-hospital anaphylaxis in elderly patients, 31 but there is no previous published information regarding the perioperative setting. The i.v. and i.m. routes are both recommended for the treatment of perioperative anaphylaxis; the i.v. route restricted to patients with continuous vital-signs monitoring, including continuous electrocardiography. 9 The AAGBI guidelines recommend an initial i.v. dose of 50 mg, repeated as necessary. 3 The Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) guidance for Grade 3 reactions recommend an initial i.v. dose of 100 mg followed, if necessary, by 100e200 mg every 1e2 min and a continuous infusion after three i.v. boluses. 10 We were not able to determine whether larger doses are more effective, but we found no important complications of repeated doses of 50 mg. However, those patients who died were more likely to be elderly and to have cardiac disease than survivors. Several died after prolonged cardiac arrest with approximately half developing multiorgan failure after transfer to critical care. In one in five cases, epinephrine was either not administered or was delayed. An apparent reluctance to give epinephrine has been previously reported, although this was not common. 32 We suggest that four factors operate. First, anaphylaxis is very uncommon: an anaesthetist will see perioperative anaphylaxis on average only once every 7.25 yr. 21 Second, when faced with hypotension, it has been the anaesthetist's previous experience that repeated doses of the 'usual' vasopressors will eventually restore arterial BP, encouraging a 'more of the same' approach. Third is the phenomenon of crisis-denial and the realisation that giving epinephrine will affirm that a crisis exists. Fourth, unless the anaesthetist has a critical care background, administration of epinephrine can be outside their usual experience. It is also possible that the anaesthetist has unfounded concerns that epinephrine is contraindicated in patients with coronary artery disease or in obstetric patients. In addition to immediate availability of management guidelines, overcoming these barriers to epinephrine administration might benefit from frequent practice drills and, ideally, simulator training. 33 Reluctance to administer large volumes of i.v. fluids was observed more commonly, including in elderly patients and those with cardiac disease, perhaps through misplaced fears of causing fluid overload and precipitating heart failure.
Risk factors for fatal reactions
The mortality rate (3.8%) observed in NAP6 corresponds with other large series. A significant finding was the association with increased age, increased ASA physical status, morbid obesity, coronary artery disease and b-blocker and angiotensin converting enzyme inhibitor use. These factors are likely to interact and might not each be independent predictors of poor outcome but are worthy of further research.
Management of profound hypotension
Patients with profound hypotension had poorer quality of care than any other patient group. They were more likely to have delayed diagnosis and administration of epinephrine, and chest compressions were a rarity. Significant numbers of patients in this group came to harm. Early recognition of these patients as at high risk of harm, early management with epinephrine and fluids, and chest compressions provide an opportunity to improve outcomes.
Critical care
Gibbison and colleagues 34 showed that perioperative anaphylaxis accounted for a third of all cases of anaphylaxis admitted to critical care units 34 ; this is a similar proportion to that admitted from the emergency department after community anaphylaxis. Our data for 144 admissions over a 1 yr period are compatible with these findings. A novel finding is that while almost two-thirds of patients admitted to critical care required continuing inotropic support, only 5% needed continuing bronchodilator therapy. Of note, there were no cases of so-called biphasic anaphylaxis.
Vasopressin and glucagon
Vasopressin is recommended for intractable hypotension in several guidelines, 5,10 but was administered in only two cases despite the presence of persistent hypotension, evidenced by the administration of norepinephrine infusion in almost one in five cases. Several cardiac arrests were preceded by prolonged hypotension. Of note, earlier guidelines omitted this drug 3 and it is likely that awareness of its role is limited. It is also likely that vasopressin is unavailable in many anaesthetising sites, a situation addressed by our recommendations. Similar comments apply to glucagon.
Chlorphenamine
We sought to be in a position to make firm recommendations about the administration of chlorphenamine. Using level of harm as the outcome and including all putative factors, logistic regression identified chlorphenamine administration was associated with increased probability of 'no harm' and decreased probability of 'moderate/severe' harm. However, the confidence intervals were wide and a Fischer exact test demonstrated that anaesthetists who gave overall good care as determined by the review panel were more likely to have administered chlorphenamine, presumably as a result of following UK guidelines (i.e. we were unable to demonstrate causality). The review panel considered that chlorphenamine should continue to be recommended, although mainly to reduce angioedema/urticaria.
Sugammadex
Several case reports may be considered supportive of administration of sugammadex during rocuronium-induced anaphylaxis. 35e37 The hypothesis that encapsulating the antigen might halt the clinical features of anaphylaxis is unproved, despite in vitro and clinical studies. 38 Platt and colleagues 39 reported sugammadex administration for immediate management of suspected rocuronium-induced anaphylaxis in 13 cases, of which five were not rocuroniuminduced. Clinical features improved in six patients, including three without rocuronium-induced anaphylaxis. This raises the possibility that sugammadex exerts a vasopressor effect via a mechanism other than encapsulating the antigen. Our data do not support the efficacy of sugammadex in rocuronium-induced anaphylaxis. Of seven proved cases, four required no further pharmacological treatment after sugammadex was given, but three required further vasopressor or bronchodilator therapy.
Anaphylaxis packs
Anaphylaxis packs 5, 40 can refer to packs designed to assist either treatment or in initiating investigation and referral. We have recommended both anaesthetic anaphylaxis treatment packs and anaesthetic anaphylaxis investigation packs. The suggested contents of these are described in Supplementary material A and B, respectively.
Decision whether to continue surgery
The majority of patients in our cohort required transfer to critical care, mostly for level 3 care, and half of patients required catecholamine infusions and a substantial number of patients were harmed by their anaphylactic event. While the decision to abandon or continue surgery needs to be a balanced one based on individual circumstances, the review panel suggest that it is inadvisable for surgery to proceed after life-threatening anaphylaxis (Grades 3 and 4), unless there are over-riding reasons to do so. Sadleir and colleagues 41 demonstrated that patients with Grade 3 anaphylaxis who continued with surgery did not require more intra-operative epinephrine or longer postoperative ventilation than those in whom the procedure was abandoned. However, surgery was more likely to be abandoned in the more severe Grade 3 cases. The authors attempted to control for this effect by using the degree of mast cell tryptase increase as a surrogate for severity, but NAP6 data show no relationship between acute mast cell tryptase concentrations and indices of clinical severity. 25 In the Sadleir and colleagues 41 study, continuing with surgery in Grade 4 anaphylaxis was not recommended because of poor outcomes in all patient groups. When surgery is abandoned there might be a need to reorganise it before allergy clinic investigation can be undertaken. Balancing the risks of deferring or proceeding with surgery after perioperative anaphylaxis will often require careful multidisciplinary discussion. The potential risks of this are underlined by a NAP6 case in which an neuromuscular blocking agent was the suspected culprit but chlorhexidine was demonstrated to be the cause on allergy testing. In most circumstances, genuinely urgent surgery can be performed before allergy clinic assessment by applying some simple, cautious rules, and we have developed a management plan (Appendix 1) for patients in whom surgery is needed before a clinic diagnosis has been obtained. However, we emphasise that this applies only to genuinely urgent surgery and that elective surgery should be deferred until after investigation. This might require multidisciplinary discussion to balance the benefits and risks of early surgery and anaesthesia.
Obstetric cases
Anaphylaxis in the obstetric setting was half as frequent as in the general adult population. Anaphylaxis during pregnancy is very uncommon including during Caesarean delivery (z1.6e3.0 per 100 000 maternities and 2.1 per 100 000 NAP6: Management, outcomes, and recommendations -181
Caesarean sections).
42e44 Widespread use of neuraxial techniques is likely to limit exposure to many trigger agents associated with general anaesthesia. Previous studies have highlighted latex, succinylcholine, and antibiotics as culprits. 45 Of note, the obstetric setting leads to numerous other (more common) obstetric causes of profound hypotension that might complicate diagnosis and delay treatment. Treatment of perioperative obstetric anaphylaxis demands safety of both patients and raises concerns of the potential impact of both maternal hypotension and epinephrine administered to the mother on uteroplacental haemodynamics. The placenta is metabolically active and metabolises histamine and other endogenous mediators, 46 potentially protecting the fetus from mediator-related morbidity. Management and outcomes of these patients was good. Phenylephrine was more widely used in obstetric anaphylaxis than in other settings; it is widely available and recommended for management of hypotension associated with spinal anaesthesia. 47 However, epinephrine remains recommended for the management of obstetric anaphylaxis, and any theoretic impact on the uteroplacental circulation is likely to be short lived 48 and less dangerous than the impact of maternal hypotension.
Paediatric cases
Perioperative anaphylaxis is uncommon in children, and reported incidences vary considerably. 49e51 We found a rate that is a quarter of that in adults. Latex and neuromuscular blocking agents have historically been prominent triggers and antibiotics less commonly cited. This is probably influenced by differences in both procedures commonly undergone by children and by anaesthetic techniques. The low incidence of paediatric perioperative anaphylaxis could have several causes. Latex exposure has reduced significantly in recent years. It is also likely that children are both less sensitised to allergens before anaesthesia and less exposed than adults to allergens during the perioperative period. NAP6 indicates that neuromuscular blocking agents and antibiotics were used in 25% and 26% of paediatric general anaesthetics, compared with 47% and 57% in adults. 24 The NAP6 allergen survey also showed that 14% of children received only sevoflurane for induction and maintenance, which is a low anaphylaxis-risk anaesthetic. 24 Unlike in adult patients, bronchospasm or high airway pressures were the most common presenting feature in children. Cardiopulmonary resuscitation was not performed in any paediatric case: in four cases, systolic arterial pressure was <50 mm Hg, but expert opinion did not favour setting a BP below which CPR should be initiated in children.
Given the small number of cases reported in children, it is not possible to make confident conclusions concerning risk rates with different drugs. However, the number of cases of atracurium and succinylcholine appears to be proportionate to the number of exposures. Atracurium was the most-used neuromuscular blocking agent in children (57%) by a large margin, followed by rocuronium, and succinylcholine. Paediatric cases are increasingly intubated without an neuromuscular blocking agent. 52 There were no cases of latex-induced anaphylaxis, which might reflect its declining presence in the workplace 53 and an increased awareness as a potential hazard following historical paediatric case reports. 54 In both obstetric and paediatric anaesthesia, we noted statistically significantly lower rates of perioperative anaphylaxis than in non-obstetric adults and adults, respectively. However, given the relatively small numbers of cases involved, these results must be interpreted with caution and require further confirmation in other series.
Recommendations
We are not aware of other studies that investigated a wide range of physical and psychological adverse sequelae. Severe anxiety and mood changes, mild/moderate memory impairment, and impaired mobility were observed. Physical harm was uncommon but did include one front of neck airway and a small number of patients who experienced myocardial infarction, acute kidney injury, or new shortness of breath as a consequence of perioperative anaphylaxis or during their recovery. It is likely that these sequelae are underdiagnosed. We recommend that all patients should be followed-up after perioperative anaphylaxis. In order to facilitate this and the many other tasks that are needed for a department of anaesthesia to be 'institutionally prepared' to manage perioperative anaphylaxis, we recommend that all departments of anaesthesia should have a 'Departmental Lead for Anaphylaxis'. The suggested roles and responsibilities are set out in Supplementary material C.
We list the complete series of NAP6 recommendations intended to improve care in Appendix 2. They are numerous and some simply reinforce known good practice. However, each recommendation is founded on the direct and indirect findings of NAP6. We hope that (as with previous NAPs) 55,56 the many recommendations we have made will be largely implemented. Others might stimulate discussion or provide hypotheses for future research. We hope this will both increase awareness of the topic and improve institutional and individual preparedness for these infrequent but life-threatening events. This will have the potential to make inroads into avoiding avoidable anaphylaxis, improving the quality of care patients receive when it occurs and afterwards, both by anaesthetists and in allergy clinics.
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Obstetric
Institutional 79. Obstetric units should ensure immediate availability of anaesthetic anaphylaxis treatment and investigation packs wherever general or regional anaesthesia is administered.
Individual
80. An allergy history should be obtained even when there is extreme urgency to deliver the baby. 81. Anaesthetists should be vigilant to non-obstetric causes of hypotension in obstetric patients. 82. Anaphylaxis in obstetric patients should be managed following the same principles as in non-obstetric patients. Epinephrine should not be withheld for fear of a detrimental effect on placental perfusion. 83. Anaphylaxis should be actively considered where the cause of maternal hypotension or collapse is unclear, and mast cell tryptase concentrations should be measured. 84. Anaesthetists should be aware that hypotension as a result of anaphylaxis can be exacerbated by neuraxial block and or aortocaval compression.
Paediatric
Institutional 85. Protocols and anaesthetic anaphylaxis treatment and investigation packs appropriate for children should be immediately available wherever paediatric anaesthesia is administered 86. All anaesthetists administering anaesthesia to children should be trained in the management of paediatric anaphylaxis. 87. The preparation of drugs for management of paediatric anaphylaxis may be prone to error in the emergency setting. Paediatric anaesthetists should consider rehearsal of drills locally or in a simulation setting.
Critical care Institutional 88. Patients with severe anaphylaxis should be admitted to critical care (HDU/ICU).
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